Skip to main content

Table 5 Adverse events in the study

From: Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma

  No. of patients with CTCAE grade (%)
Adverse event 1 (%) 2 (%) 3 (%) 4 (%)
AST/ALT 21 (55.3) 6 (15.8) 4 (10.5) 1 (2.6)
Alkaline-phosphatase 3 (7.9)
Bilirubin 12 (31.6) 2 (5.3) 3 (7.9) 2 (5.3)
Gastroduodenitis 2 (5.3) 1 (2.6)
Gastric ulcer 2 (5.3) 1 (2.6)
Duodenal ulcer 1 (2.6) 1 (2.6)
  1. CTCAE Common Terminology Criteria for Adverse Events, AST aspartate aminotransferase, ALT alanine aminotransferase